Karin Kleinhans
Private Equity Investor bij Merck Research Ventures
Profiel
Karin Kleinhans is currently a Partner at Merck Research Ventures since 2002 and an Advisor at Berlin Institute of Health since 2021.
She was previously a Director at Cardior Pharmaceuticals GmbH from 2017 to 2022, a Director at Arcum Therapeutics, Inc. from 2021 to 2022, a Director at T-Knife GmbH in 2021, and a Partner at EQT Partners GmbH and LSP Services Deutschland GmbH from 2015 to 2022.
Kleinhans received her undergraduate, graduate, and doctorate degrees from Universität Ulm in 2010 and 2014.
Actieve functies van Karin Kleinhans
| Bedrijven | Functie | Begin |
|---|---|---|
Merck Research Ventures
 Merck Research Ventures Investment ManagersFinance Merck Research Ventures (Merck Research) is a venture capital subsidiary of Merck Research Laboratories Massachusetts LLC founded in 2000. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01-01-2002 |
| Berlin Institute of Health | Consultant / Adviseur | 01-01-2021 |
Eerdere bekende functies van Karin Kleinhans
| Bedrijven | Functie | Einde |
|---|---|---|
| EQT Partners GmbH | Private Equity Investor | 31-12-2022 |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Directeur/Bestuurslid | 31-12-2022 |
Arcum Therapeutics, Inc.
 Arcum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcum Therapeutics, Inc. develops pharmaceutical drug products. It provides technologies aim at therapeutic intervention of multidrug-resistant bacterial infections. The company was founded by Paul M. Dunman and is headquartered in Pittsford, NY. | Directeur/Bestuurslid | 31-12-2022 |
| LSP Services Deutschland GmbH | Private Equity Analist | 02-01-2022 |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Directeur/Bestuurslid | 31-12-2021 |
Opleiding van Karin Kleinhans
| Universität Ulm | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
| EQT Partners GmbH | Finance |
| LSP Services Deutschland GmbH | Finance |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures (Merck Research) is a venture capital subsidiary of Merck Research Laboratories Massachusetts LLC founded in 2000. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Health Technology |
| Berlin Institute of Health | |
Arcum Therapeutics, Inc.
Arcum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcum Therapeutics, Inc. develops pharmaceutical drug products. It provides technologies aim at therapeutic intervention of multidrug-resistant bacterial infections. The company was founded by Paul M. Dunman and is headquartered in Pittsford, NY. | Health Technology |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
